$
27.700
-0.14(-0.503%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
29.325
Open
29.230
VWAP
28.60
Vol
17.38K
Mkt Cap
187.94M
Low
27.500
Amount
497.00K
EV/EBITDA(TTM)
--
Total Shares
6.50M
EV
180.54M
EV/OCF(TTM)
--
P/S(TTM)
--
Instil Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. The Company seeks to in-license/acquire and develop novel therapeutic candidates in diseases with significant unmet medical need. The Company’s subsidiary, Axion Bio, Inc., in-licensed certain bispecific antibodies, including AXN-2510/IMM2510 and AXN-27M/IMM27M, a monoclonal antibody targeting cytotoxic T-lymphocyte associated antigen 4, or CTLA-4. AXN-2510/IMM2510, the lead in-licensed product candidate, is a novel and differentiated PD-L1xVEGF bispecific antibody in development for the treatment of multiple solid tumor cancers. AXN-27M/IMM27M is an antibody-dependent cellular cytotoxicity-enhanced monoclonal antibody targeting CTLA-4, which has been designed to promote intratumoral regulatory T cell depletion to enhance the efficacy and reduce the toxicity associated with first-generation anti-CTLA-4 antibodies.
Show More
Intellectia AI SwingMax
2 Analyst Rating
up
Wall Street analysts forecast TIL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TIL is 125.00 USD with a low forecast of 125.00 USD and a high forecast of 125.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
1 Hold
0 Sell
Moderate Buy
up
Current: 27.700
sliders
Low
125.00
Averages
125.00
High
125.00
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$105 -> $125
2025-05-23
Reason
H.C. Wainwright raised the firm's price target on Instil Bio to $125 from $105 and keeps a Buy rating on the shares after the company released Phase 1/2 dose escalation data for AXN-2510 in first-line non-small cell lung cancer. The firm increased its probability of approval to 35% from 25%.
H.C. Wainwright
Buy
downgrade
$110 -> $105
2025-05-22
Reason
H.C. Wainwright lowered the firm's price target on Instil Bio to $105 from $110 and keeps a Buy rating on the shares following the Q1 report. The firm says Pfizer's "lucrative" PD-1 x VEGF bispecific deal underscores the attractiveness of tumor-infiltrating lymphocytes. The rising values of these transactions should provide further confidence that the highly positive clinical impact of these PD-1/L1 x VEGF bispecifics is real, the analyst tells investors in a research note.
HC Wainwright & Co.
Mitchell Kapoor
Strong Buy
Reiterates
$110
2025-03-05
Reason
JMP Securities
Chris Muller
Hold
Reiterates
n/a
2025-02-13
Reason
Jefferies
Kelly Shi
Hold
to
Strong Buy
Upgrades
$11 → $52
2025-01-07
Reason
Jefferies upgraded Instil Bio to Buy from Hold with a price target of $52, up from $11.
HC Wainwright & Co.
Mitchell Kapoor
Strong Buy
Reiterates
$110
2024-11-18
Reason

Valuation Metrics

The current forward P/E ratio for Instil Bio Inc (TIL.O) is -2.72, compared to its 5-year average forward P/E of -4.38. For a more detailed relative valuation and DCF analysis to assess Instil Bio Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.38
Current PE
-2.72
Overvalued PE
0.40
Undervalued PE
-9.16

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-3.23
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
2.36
Undervalued EV/EBITDA
-8.82

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
2987.29
Current PS
0.00
Overvalued PS
13092.09
Undervalued PS
-7117.51
Financial AI Agent

Financials

Annual
Quarterly
FY2025Q2
N/A
Total Revenue
FY2025Q2
YoY :
-5.33%
-12.90M
Operating Profit
FY2025Q2
YoY :
-100.00%
N/A
Net Income after Tax
FY2025Q2
YoY :
+41.48%
-3.24
EPS - Diluted
FY2025Q2
YoY :
+39.38%
-14.79M
Free Cash Flow
FY2025Q2
N/A
Gross Profit Margin - %
FY2025Q2
N/A
FCF Margin - %
FY2025Q2
N/A
Net Margin - %

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
38.9K
Volume
1
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
1
355.5K
Volume
Months
0-12
1
355.5K
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
AI Stock Picker

TIL News & Events

Events Timeline

2025-07-31 (ET)
2025-07-31
06:18:49
Instil Bio: ImmuneOnco reports results from Phase 2 study of IMM2510/AXN-2510
select
2025-07-02 (ET)
2025-07-02
06:01:35
Instil Bio announces FDA clearance of IND application for AXN-2510
select
2025-06-11 (ET)
2025-06-11
07:16:04
Instil Bio adds Maraganore to the Board of Directors of Axion Bio
select
Sign Up For More Events

News

9.5
08-13Newsfilter
Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update
9.5
08-13NASDAQ.COM
Instil Bio Posts Wider Loss in Q2
9.0
07-31Newsfilter
ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in China
Sign Up For More News

FAQ

arrow icon

What is Instil Bio Inc (TIL) stock price today?

The current price of TIL is 27.7 USD — it has decreased -0.5 % in the last trading day.

arrow icon

What is Instil Bio Inc (TIL)'s business?

arrow icon

What is the price predicton of TIL Stock?

arrow icon

What is Instil Bio Inc (TIL)'s revenue for the last quarter?

arrow icon

What is Instil Bio Inc (TIL)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Instil Bio Inc (TIL)'s fundamentals?

arrow icon

How many employees does Instil Bio Inc (TIL). have?

arrow icon

What is Instil Bio Inc (TIL) market cap?